Remimazolam vs Propofol as an Induction Agent for Morbid Obesity Patients
Status:
Recruiting
Trial end date:
2023-09-12
Target enrollment:
Participant gender:
Summary
It is known that morbidly obese patients are often accompanied by cardiovascular
complications such as hypertension, cardiac hypertrophy, and diastolic dysfunction, and are
known to increase the risk of hypotension during anesthesia induction. Remimazolam is widely
used in Japan and the United States, and it was approved as a drug for general anesthesia and
sedation in Korea in 2021. It was reported that remimazolam caused less hypotension after
induction of anesthesia than propofol. However, there is no study on the use of remimazolam
in patients undergoing bariatric surgery due to morbid obesity. Therefore, through this
study, we plan to check whether remimazolam is safe and effective as an anesthetic-inducing
agent for morbidly obese patients undergoing bariatric surgery.